View Older Stories View More Recent Stories

Jun 20, 2019 09:30AM VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease, Without The Psychological Side Effects And Saf
May 30, 2019 08:30AM VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side Effects
May 7, 2019 08:30AM VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China
May 2, 2019 07:00AM VistaGen Reports Top Line Results from NIMH's Exploratory Study of AV-101 Monotherapy for Treatment-Resistant Depression
Apr 3, 2019 08:30AM VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019
Apr 1, 2019 08:36AM VistaGen (VTGN) announces additional results from positive pilot Phase 3 study of PH94B
Apr 1, 2019 08:30AM Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder
Mar 28, 2019 08:32AM VistaGen Therapeutics (VTGN) Granted Australian Patent for Treatment of Depression with AV-101
Mar 28, 2019 08:30AM VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101
Mar 14, 2019 08:30AM VistaGen Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019
Mar 13, 2019 08:36AM VistaGen Therapeutics (VTGN) Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101
Mar 13, 2019 08:30AM VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101
Mar 7, 2019 09:35AM VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019
Feb 19, 2019 08:37AM VistaGen Therapeutics (VTGN) Granted Japanese Patent for AV-101 for Treatment of Depression and Hyperalgesia
Feb 19, 2019 08:30AM VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia
Feb 19, 2019 08:30AM VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia
Feb 13, 2019 08:36AM VistaGen Therapeutics (VTGN) Granted U.S. Patent Related to Methods for Treating Depression with PH10
Feb 13, 2019 08:30AM VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
Feb 13, 2019 08:30AM VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
Feb 12, 2019 04:49PM VistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial Results
Feb 12, 2019 04:49PM VistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial Results
Feb 5, 2019 08:30AM VistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019
Feb 5, 2019 08:30AM VistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019
Jan 31, 2019 08:34AM VistaGen Therapeutics (VTGN) Says AV-101 Stimulates Formation of New Brain Cells in Nonclinical Studies
Jan 31, 2019 08:30AM AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies
Jan 31, 2019 08:30AM AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies
Jan 15, 2019 08:32AM VistaGen Therapeutics (VTGN) Appoints Ann Cunningham to Board
Jan 15, 2019 08:30AM VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors
Jan 15, 2019 08:30AM VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors
Dec 27, 2018 08:30AM VistaGen Therapeutics to Present at 11th Annual Biotech Showcase
Dec 27, 2018 08:30AM VistaGen Therapeutics to Present at 11th Annual Biotech Showcase
Nov 29, 2018 08:32AM VistaGen Therapeutics (VTGN) Receives Hong Kong Patent for Methods of Production for AV-101
Nov 29, 2018 08:30AM VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101
Nov 29, 2018 08:30AM VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101
Nov 12, 2018 08:50AM VistaGen Therapeutics (VTGN) Granted Notices of Allowance in Australia & Japan for AV-101 Patents Covering Treatment of Depression
Nov 12, 2018 08:30AM VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
Nov 12, 2018 08:30AM VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
Oct 29, 2018 04:30PM VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results
Oct 29, 2018 04:30PM VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results
Oct 25, 2018 09:03AM VistaGen Therapeutics (VTGN) Acquires Worldwide Rights to Develop and Commercialize PH10 for MDD
Oct 25, 2018 09:00AM VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depr
Oct 25, 2018 09:00AM VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depr
Oct 22, 2018 08:30AM VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018
Oct 15, 2018 08:30AM VistaGen Therapeutics Appoints Dr. Michael Liebowitz to CNS Clinical and Regulatory Advisory Board in Preparation for Pivotal Phase 3 Development of PH94B as the First Rapid-Acting, On-Demand Treatmen
Oct 3, 2018 08:31AM VistaGen Therapeutics (VTGN) Granted FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
Oct 3, 2018 08:30AM VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
Oct 3, 2018 08:30AM VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
Sep 13, 2018 08:34AM VistaGen Therapeutics (VTGN) Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for Treatment of SAD
Sep 13, 2018 08:30AM VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder
Sep 13, 2018 08:30AM VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder
View More Recent Stories View Older Stories